African American Women with Cyp3a4/5 Polymorphisms Have Increased Statin Intolerance

Mohammad, Somayya J.; Schwendeman, Ethan; Dib, Patrick; Milks, M. Wesley; McDougle, Leon; Binkley, Philip F.; Smith, Sakima A.

doi:10.1016/j.jvssci.2022.05.037

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, we found relevant results for atorvastatin and simvastatin, the statins with the greatest prevalence of use in the study population and overall. 34,35 Another important finding of our study is that the clinical benefits of statins in COVID-19 would not seem to be due to a class effect, in view of the variability observed in the estimated ORs of the respective active ingredients. Indeed, there is strong evidence to show that statins display independent pleiotropic effects of the common lipid-lowering mechanism of action and that these differ among the active ingredients.…”

Section: Susceptibility To the Virusmentioning

confidence: 62%

See 1 more Smart Citation

Outpatient atorvastatin use and severe COVID‐19 outcomes: A population‐based study

Visos‐Varela,

Zapata‐Cachafeiro,

Pintos‐Rodríguez

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Evidence of the effect of statins on patients with coronavirus disease (2019) COVID-19 is inconsistent. The aim of this study was to evaluate the association between chronic use of statins-both overall and by active ingredient-and severe outcomes of COVID-19 (risk of hospitalization and mortality), progression to severe outcomes, and susceptibility to the virus. We conducted a populationbased case-control study with data from electronic records to assess the risk of (1) hospitalization: cases were patients admitted due to COVID-19 and controls were subjects without COVID-19; (2) mortality: cases were hospitalized patients who died due to COVID-19 and controls were subjects without COVID-19; (3) progression: cases were hospitalized COVID-19 subjects and controls were nonhospitalized COVID-19 patients; and (4) susceptibility: cases were patients with COVID-19 (both hospitalized and nonhospitalized) and controls were subjects without COVID-19.We collected data on 2821 hospitalized cases, 26 996 nonhospitalized cases, and 52 318 controls. Chronic use of atorvastatin was associated with a decreased risk of hospitalization (adjusted odds ratios [aOR] = 0.83; 95% confidence interval [CI]: 0.74-0.92) and mortality (aOR = 0.70; 95% CI: 0.53-0.93), attributable in part to a lower risk of susceptibility to the virus (aOR = 0.91; 95% CI: 0.86-0.96). Simvastatin was associated with a reduced risk of mortality (aOR = 0.59; 95% CI: 0.40-0.87). The wide degree of heterogeneity observed in the estimated odds ratios (ORs) of the different statins suggests that there is no class effect. The results of this real-world study suggest that chronic use of atorvastatin (and to a lesser degree, of simvastatin) is associated with a decrease in risk of severe COVID-19 outcomes.

show abstract

Section: Susceptibility To the Virusmentioning

confidence: 62%

“…We were thus able to ascertain the role played by each in the clinical course of the disease. Specifically, we found relevant results for atorvastatin and simvastatin, the statins with the greatest prevalence of use in the study population and overall 34,35 …”

Section: Discussionmentioning

confidence: 78%